Primary Meningioma WHO grade III
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA630521 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Comparative transcriptomic analysis of n=10 primary Meningioma WHO grade III
2020-11-05 | GSE149923 | GEO
Project description:Genomic profiling of anaplastic meningioma can inform prognostic gene level alterations in lower-grade meningiomas, potentially reflecting evolution of anaplastic meningioma from lowergrade precursor tumours. Larger scale studies in paired primary and recurrent meningiomas are warranted to unravel the evolutionary path to anaplastic meningiomas and prognostic genomic alterations in detail
2021-05-04 | GSE173825 | GEO
Project description:High-grade meningioma remains a therapeutic challenge to medical oncologists. It is urgent to uncover novel molecular targets. Solute carrier family 7 member 1 (SLC7A1) was highly expressed in high-grade meningioma and associated with poor prognosis of patients. SLC7A1 knockdown significantly inhibited the proliferation and invasion of malignant meningioma cells. In addition, the small-molecule drug AZ628 showed an excellent antiproliferative effect on malignant meningioma cells, indicating that it is a potential antitumor drug for high-grade meningioma. Our study revealed the essential roles of SLC7A1 in the malignant progression of meningioma, suggesting SLC7A1 as a potential antitumor target for high-grade meningioma.
2025-09-27 | GSE244554 | GEO
Project description:Meningiomas are common brain tumors that are classified into three World Health Organization grades (Grade I: benign, Grade II: atypical and Grade III: malignant) and are molecularly ill-defined tumors. The purpose of this study was identify microRNA (miRNA) molecular signatures unique to the different grades of meningiomas correlating them to prognosis. We have used a miRNA expression microarray to show that meningiomas of all three grades fall into two main molecular groups designated “benign” and “malignant” meningiomas. While all typical meningiomas fall into the benign group and all anaplastic meningiomas fall into the malignant group, atypical meningiomas distribute into either one of these groups. We have identified a miRNA signature that distinguishes benign meningiomas from malignant meningiomas. We studied the gene expression profiles of 340 mammalian miRNAs in 37 primary meningioma tumors by means of DNA microarrays.
2011-01-02 | E-GEOD-19720 | biostudies-arrayexpress
Project description:Although meningiomas are one of the most frequent primary intracranial tumors, there are only a few studies dealing with gene regulation processes in meningiomas. MiRNAs are key regulators of gene expression and regulation and miRNA profiles offer themselves as biomarkers for cancer development and progression. To investigate the role of miRNAs during meningioma growth and progression, we compared expression of 1205 miRNAs in 55 meningioma samples of different tumor grades and histological subtypes. We were able to classify histological subtypes in WHO grade I meningiomas with up to 97% accuracy (meningothelial versus fibroblastic) and different WHO grades with up to 93% accuracy (WHO I versus WHO III). We found significant downregulation of miRNAs on chromosome 1p36 and within two large miRNA clusters on 14q32 in high grade meningiomas, two regions that are yet associated with meningioma progression. We also identified several miRNAs associated with epithelial to mesenchymal transition differentially expressed in meningothelial meningioma compared to fibroblastic meningioma. Combined, our data show that meningiomas of different WHO grades and histological subtypes show a specific miRNA expression profile. Some individual miRNAs can also serve as potential biomarkers for meningioma progression.
2014-12-31 | GSE50641 | GEO
Project description:We performed expression profiling of 24 meningioma and two dura controls analyzing 55000 transcripts including 18300 known genes. We compared expression in meningioma vs. dura, expression of low grade (WHO I) vs. higher-grade (WHO II and WHO IIII) tumors and expression of meningothelial and syncytial meningioma vs. fibroblastic meningioma. Gene expression was analysed in 24 meningioma including eight of each WHO grade and two dura controls analyzing 55000 transcripts including 18300 known genes.
2008-11-20 | E-GEOD-12530 | biostudies-arrayexpress
Project description:Meningiomas, the most common primary brain tumours, are classified by the World Health Organization (WHO) into grades 1, 2, and 3. Some grade 1 tumours exhibit increased clinical aggressiveness with the biallelic mutation of Neurofibromatosis 2 (NF2) being the most frequent mutation reported. In our study, we analysed the most common driver mutations (NF2, AKT1, KLF4, and TRAF7) in meningioma by proteomics and genomics focussing on lower grade tumours. Our genomic data revealed co-occurrences of non-NF2 mutations in lower-grade meningiomas suggesting synergistic effects supporting tumour growth. NF2-/- meningiomas showed distinct proteomic clustering, with different mutations found in these clusters. Additionally, proteomics identified ANXA3 in NF2-/- meningioma and its role in proliferation was confirmed in grade1 and subsequently grade 3 tumours in vitro and with abolished growth when tested in meningioma mouse model. These findings highlight new targets in different meningioma backgrounds presenting ANXA3 as a potential therapeutic target for meningioma treatment.
2025-07-02 | PXD058653 | Pride
Project description:Meningiomas, the most common primary brain tumours, are classified by the World Health Organization (WHO) into grades 1, 2, and 3. Some grade 1 tumours exhibit increased clinical aggressiveness with the biallelic mutation of Neurofibromatosis 2 (NF2) being the most frequent mutation reported. In our study, we analysed the most common driver mutations (NF2, AKT1, KLF4, and TRAF7) in meningioma by proteomics and genomics focussing on lower grade tumours. Our genomic data revealed co-occurrences of non-NF2 mutations in lower-grade meningiomas suggesting synergistic effects supporting tumour growth. NF2-/- meningiomas showed distinct proteomic clustering, with different mutations found in these clusters. Additionally, proteomics identified ANXA3 in NF2-/- meningioma and its role in proliferation was confirmed in grade1 and subsequently grade 3 tumours in vitro and with abolished growth when tested in meningioma mouse model. These findings highlight new targets in different meningioma backgrounds presenting ANXA3 as a potential therapeutic target for meningioma treatment
2025-07-02 | PXD058651 | Pride
Project description:We performed expression profiling of 24 meningioma and two dura controls analyzing 55000 transcripts including 18300 known genes. We compared expression in meningioma vs. dura, expression of low grade (WHO I) vs. higher-grade (WHO II and WHO IIII) tumors and expression of meningothelial and syncytial meningioma vs. fibroblastic meningioma.
2008-11-21 | GSE12530 | GEO
Project description:Tumor development relies on numerous factors, including the capacity to adapt to hypoxic conditions. Hypoxic microenvironment is a critical driver of the malignant phenotype, which is often correlated with meningioma grade, aggressive behavior, therapeutic resistance, and higher recurrence rates, leading to poor prognosis. Hence, the exploration of genes involved in tumor adaptation to hypoxia can reveal novel molecular targets for the development of hypoxia-targeted therapeutics for meningioma.
2026-02-18 | GSE282349 | GEO